Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology

This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lympho...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Lasek, Witold (Συγγραφέας), Zagozdzon, Radoslaw (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2016.
Σειρά:SpringerBriefs in Immunology,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 02619nam a22005415i 4500
001 978-3-319-46906-5
003 DE-He213
005 20160923120258.0
007 cr nn 008mamaa
008 160923s2016 gw | s |||| 0|eng d
020 |a 9783319469065  |9 978-3-319-46906-5 
024 7 |a 10.1007/978-3-319-46906-5  |2 doi 
040 |d GrThAP 
050 4 |a QR180-189.5 
072 7 |a MJCM  |2 bicssc 
072 7 |a MED044000  |2 bisacsh 
082 0 4 |a 616.079  |2 23 
100 1 |a Lasek, Witold.  |e author. 
245 1 0 |a Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology  |h [electronic resource] /  |c by Witold Lasek, Radoslaw Zagozdzon. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2016. 
300 |a VII, 75 p. 6 illus.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a SpringerBriefs in Immunology,  |x 2194-2773 
520 |a This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). 
650 0 |a Medicine. 
650 0 |a Cancer research. 
650 0 |a Immunology. 
650 0 |a Oncology. 
650 0 |a Cytokines. 
650 0 |a Growth factors. 
650 0 |a Cell biology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Immunology. 
650 2 4 |a Cancer Research. 
650 2 4 |a Cytokines and Growth Factors. 
650 2 4 |a Oncology. 
650 2 4 |a Cell Biology. 
700 1 |a Zagozdzon, Radoslaw.  |e author. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319469058 
830 0 |a SpringerBriefs in Immunology,  |x 2194-2773 
856 4 0 |u http://dx.doi.org/10.1007/978-3-319-46906-5  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)